Drug Database
FL

fluoxetine (EDG005)

✓ Approved

Edgemont Pharmaceuticals, LLC · SLC6A4 · Small Molecule

What is fluoxetine?

fluoxetine is a small molecule developed by Edgemont Pharmaceuticals, LLC. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesEDG005
CompanyEdgemont Pharmaceuticals, LLC
Drug ClassSmall Molecule
Molecular TargetSLC6A4
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

fluoxetine acts on 1 molecular target:

SLC6A4solute carrier family 6 member 4 (5HTT, 5-HTT)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

fluoxetine is developed for 4 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersBulimia nervosa✓ Approved
Psychiatric disordersObsessive-compulsive disorder✓ Approved
Psychiatric disordersPanic disorder✓ Approved
Psychiatric disordersMajor depression✓ Approved

Related Research Articles

PubMedThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2026-10-13

Chemical Stability of Atomoxetine Hydrochloride and Fluoxetine Hydrochloride Oral Anhydrous Extemporaneously Compounded Suspensions.

Ip Kendice K, Davis Courtaney C, Vu Christine C, Pramar Yashoda V YV et al.

Atomoxetine is indicated for the treatment of attention-deficit/hyperactivity disorder, and fluoxetine is commonly used for treating depression. Variable dosing per body weight is required in children, and the commercially available capsules do not offer the required flexibility and potential for customization. The objective of this study was to evaluate the physicochemical stability of atomoxetine hydrochloride and fluoxetine hydrochloride oral anhydrous extemporaneously compounded suspensions. An anhydrous suspension of atomoxetine hydrochloride was prepared from commercially available capsules at a 4-mg/mL concentration, and an anhydrous suspension of fluoxetine hydrochloride was prepared from pure drug powder at a concentration of 10 mg/mL. The extemporaneously compounded suspensions were prepared according to standardized formulas and methods of preparation. Samples were stored at refrigerated and controlled room temperatures for 6 months. The physicochemical properties of the samples were analyzed and characterized on days 0, 14, 30, 60, 90, and 180. A robust stability-indicating ultra-performance liquid chromatography assay method was validated and employed. The samples remained consistent in appearance and color, with atomoxetine forming a pale-yellow suspension and fluoxetine yielding an off-white to faint beige suspension. Both anhydrous suspensions remained within the ±10% potency specification. The percent concentration relative to labelled concentration (potency) was at or above 96.5% for atomoxetine and at or above 96.8% for fluoxetine. Beyond-use dates of 6 months at both refrigerated and room temperature conditions have been established for the atomoxetine 4-mg/mL anhydrous suspension and the fluoxetine 10-mg/mL anhydrous suspension.

PubMedZhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica2026-10-13

[Mechanistic study on Kaixin Powder ameliorating chronic stress-induced CD8~+T cell exhaustion and delaying lung adenocarcinoma progression by modulating IDO1/Kyn/Ahr axis].

Fu Xi X, Bai Yu-Ting YT, He Jia-Wei JW, Xiong Yu-Xuan YX et al.

This study aimed to investigate the interventional effects of Kaixin Powder(KXP) on the progression of lung adenocarcinoma(LUAD) under chronic stress and its underlying mechanism. Ultra-performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS) was employed to characterize the chemical constituents of KXP, followed by network pharmacology and molecular docking analyses to screen for its potential targets. A chronic stress-associated lung cancer mouse model was established by axillary inoculation of Lewis lung carcinoma(LLC) cells combined with chronic unpredictable mild stress(CUMS). Sixty SPF-grade C57BL/6 mice were randomly divided into the following groups: normal group, lung cancer group, model group, low-and high-dose KXP(13.65 and 27.3 g·kg~(-1)) groups, and fluoxetine(2 mg·kg~(-1)) group. Tumor growth indicators, including body weight, tumor mass, and tumor inhibition rate of mice were measured. Depression-like behaviors were observed by open field test(OFT) and sucrose preference test(SPT). Serum levels of stress factors such as corticosterone(Cort) and kynurenine(Kyn) were measured by ELISA. Histopathological changes in tumor tissue were assessed by hematoxylin-eosin(HE) staining. Peripheral blood T lymphocyte subsets were analyzed by flow cytometry. Intratumoral CD8~+T cells infiltration was detected by immunofluorescence, and the protein expression levels of indoleamine 2,3-dioxygenase 1(IDO1) and aryl hydrocarbon receptor(Ahr) were determined by Western blot. Serum ALT, AST, BUN, and Scr levels were measured to evaluate hepatic and renal safety. UPLC-MS/MS analysis characterized 157 chemical constituents of KXP. The protein expression levels of indoleamine 2,3-dioxygenase 1(IDO1) and aryl hydrocarbon receptor(Ahr) were detected by Western blot. In addition, serum ALT, AST, BUN, and Scr levels were measured to evaluate hepatic and renal safety. UPLC-MS identified 157 chemical constituents of KXP. Network pharmacology analysis obtained 367 potential targets, among which epidermal growth factor receptor(EGFR), protein kinase B alpha(AKT1), signal transducer and activator of transcription 3(STAT3), heat shock protein 90 alpha family class A member 1(HSP90AA1), and IDO1 were screened as core targets. Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway analysis and molecular docking indicated that abnormal tryptophan metabolism mediated by IDO1 may be a potential mechanism underlying KXP intervention in LUAD complicated with depression. Animal experiments showed that, compared with the lung cancer group, the model group exhibited significantly accelerated tumor growth, increased structural disarray and atypia in HE-stained tumor tissue, obvious depression-like behaviors, and significantly elevated serum Cort and Kyn levels. In addition, the proportions of peripheral blood CD3~+ and CD3~+CD4~+T cells and the CD3~+CD4~+/CD3~+CD8~+ ratio significantly decreased, whereas the proportion of CD3~+CD8~+T cells significantly increased. Intratumoral CD8~+T cells infiltration was reduced, while the protein expression levels of IDO1 and Ahr were significantly upregulated. Compared with the model group, the high-dose KXP group showed significantly reduced tumor volume and tumor weight, with a tumor inhibition rate of 52.43%. KXP intervention improved depression-like behaviors to varying degrees, with the high-dose group showing more pronounced improvements in OFT activity indicators and SPT sucrose preference rate. Serum Cort and Kyn levels were significantly reduced in the high-dose KXP group. The proportions of peripheral blood CD3~+ and CD3~+CD4~+T cells and the CD3~+CD4~+/CD3~+CD8~+ ratio significantly increased in both low-and high-dose KXP groups. The low-dose KXP group showed significantly reduced IDO1 protein expression, while the high-dose group showed significantly reduced expression of both IDO1 and Ahr proteins. Safety evaluation showed that, within the experimental dose range, KXP had no obvious adverse effects on the morphology of major organs or on serum ALT, AST, BUN, and Scr levels. In conclusion, KXP ameliorates chronic stress and delays LUAD progression, and its mechanism may be associated with inhibition of the IDO1/Kyn/Ahr axis, correction of abnormal tryptophan metabolism, promotion of intratumoral CD8~+T cells infiltration, and improvement of the tumor immune microenvironment.

PubMedFrontiers in immunology2026-10-11

Shared immune perturbations in hepatocellular carcinoma-depression comorbidity and synergistic immunotherapeutic effects of fluoxetine combined with anti-PD-1.

Wang Shanshan S, Gao Yunwei Y, Li Qianbin Q, Song Huimin H et al.

Hepatocellular carcinoma (HCC) often coexists with depression, elevating patient mortality by 39%. The tryptophan metabolic axis bridges tumor and neuropsychiatric immune dysfunction, yet the immunometabolic crosstalk underlying HCC-depression comorbidity remains poorly defined, and reliable combinatorial immunotherapies are absent. We integrated public multi-omics datasets including TCGA, GEO, eQTLGen and FinnGen, and performed two-sample MR as well as genetic colocalization analyses to screen hub genes associated with HCC-depression comorbidity. GSEA/GSVA, single-cell and spatial transcriptomics were adopted to dissect gene expression and perturbed tryptophan immune pathways. In silico docking predicted fluoxetine binding to BTN3A3, GLCE and RBCK1. A Hepa1-6/CUMS comorbid mouse model combined with targeted tryptophan LC-MS metabolomics, flow cytometry and ELISA was used to verify combined therapeutic effects and tissue molecular alterations. Seven overlapping risk genes for HCC and depression were identified. BTN3A3, GLCE and RBCK1 reached strict colocalization thresholds (SNP.PP.H4 > 0.90) and were predominantly expressed in T cells and M2 macrophages linked to tryptophan metabolism. Fluoxetine displayed stable binding affinity with all three hub proteins via molecular simulation. In vivo assays proved fluoxetine plus anti-PD-1 restrained tumor progression, alleviated depression-like phenotypes, normalized tissue GLCE/RBCK1 levels and restored disordered tryptophan metabolism and immunosuppressive microenvironment in comorbid mice. This work characterizes tryptophan-mediated immune disturbance in HCC-depression comorbidity. GLCE and RBCK1 correlate with comorbid immunometabolic disorders. Fluoxetine combined with anti-PD-1 exerts synergistic immunoregulatory effects by reshaping tryptophan-related immune homeostasis, offering a preclinical metabolic immunotherapy strategy for concurrent HCC and depression.

PubMedFrontiers in pharmacology2026-10-11

Interaction of major monoterpenes from Rosmarinus officinalis L. essential oil with the human serotonin transporter: molecular docking, radioligand binding, and functional uptake studies.

Valle Carolina C, Segura Kerim K, Cárdenas Pilar P, Osses Nelson N et al.

Major depressive disorder remains a leading cause of disability worldwide, and current antidepressants are limited by delayed therapeutic onset, incomplete efficacy, and adverse effects. Although Rosmarinus officinalis L. essential oil and its major monoterpenes exhibit antidepressant-like and anxiolytic properties, their molecular mechanisms remain unclear. This study investigated whether the principal rosemary monoterpenes, α-pinene, camphor, and 1,8-cineole, directly interact with the human serotonin transporter (hSERT) and its functional effects. Molecular docking simulations targeting the orthosteric (S1) and allosteric (S2) binding sites were combined with [3H]-paroxetine binding displacement assays and SERT-mediated uptake experiments based on the fluorescent serotonin analog FFN246 in HEK293 cells expressing YFP-tagged hSERT. Docking analyses predicted plausible binding poses for all three monoterpenes within both the S1 and S2 regions, although with less favorable docking scores than fluoxetine. Radioligand displacement assays provided experimental evidence that all three compounds interact with hSERT, producing concentration-dependent displacement of [3H]-paroxetine, with α-pinene displaying the highest potency, followed by 1,8-cineole and camphor. Functional assays further showed that all monoterpenes produced significant but incomplete inhibition of transporter-mediated FFN246 uptake, even at high micromolar concentrations, indicating partial rather than complete transporter blockade. Together, these findings identify hSERT as a previously unrecognized molecular target of rosemary monoterpenes, suggesting that these compounds may act as partial inhibitors of serotonin transport. These results provide new molecular insights into the potential mechanism that may contribute to the reported neurobehavioral effects of rosemary, and support further investigation of these compounds in serotonergic signaling and neurotransmission.

PubMedMarine environmental research2026-10-08

Combined effects of elevated temperature and fluoxetine exposure on early development of the sea urchin Paracentrotus lividus.

Gambardella Chiara C, Miroglio Roberta R, Soro Pietro P, Rosa Giacomo G et al.

Temperature rise associated with climate change increases the vulnerability of coastal species, which are also exposed to pharmaceuticals. We investigated the effects of thermal stress and fluoxetine (FLX), alone and in combination, on early developmental stages of the sea urchin Paracentrotus lividus, a key coastal species. Gametes, zygotes and embryos were exposed to ambient (18°C) and near-future projections (21°C, 24°C) to identify the most sensitive developmental stage to warming. In parallel, environmentally relevant FLX concentrations were tested under near-future temperature scenarios. Fertilization and embryonic development were not affected by any treatment, conversely to larval development. Larvae derived from zygotes exposed to elevated temperature, alone or combined with FLX, exhibited developmental anomalies, while reductions in body width and post-oral arm gap were found in larvae from all exposed stages under elevated temperature. Zygote was the most thermally sensitive stage, and warming enhanced FLX-related effects, reducing larval development. These findings highlight that the interaction between ocean warming and pharmaceutical contamination may increase the vulnerability of early life stages of coastal species, potentially affecting survival under future climate scenarios.

PubMedBritish journal of clinical pharmacology2026-10-08

A scoping review of adverse events associated with concomitant beta-adrenoreceptor blockers and selective serotonin reuptake inhibitors.

Cai Ziyi Z, Sutton James J, Archer Charlotte C, Copeland Caroline S CS et al.

Beta-adrenoreceptor blockers (beta-blockers) and selective serotonin reuptake inhibitors (SSRIs) are commonly used medications and often used together, such as for the treatment of anxiety. However, there is no recent review of any potential adverse events related to concomitant use of medicines from each group. This scoping review therefore aimed to provide this narrative synthesis. Key databases were searched for articles published in English from 1 January 1990 to 24 November 2025 reporting any adverse event due to the concomitant use of beta-blockers and SSRIs in people aged 18 or over. Any study design was permitted. From 2211 distinct records, 117 articles were eligible for full-text screening, and 48 articles were included. Eight of these were review articles referring to otherwise-included empirical studies. Most were interventional (n = 19, 36.9%) or case reports (n = 14, 29.2%). Bradycardia was the most frequently reported adverse event (n = 11) mostly in case reports involving metoprolol-fluoxetine, metoprolol-paroxetine, metoprolol-sertraline or propranolol-fluoxetine. Blood pressure changes (including hypotension) were observed in half of studies which explored them. Neurocognitive-related symptoms were heterogeneous and there were four case reports/series of self-poisoning suicide or self-harm. The adverse events discussed in this review could be signals for drug-drug interactions. Where mechanism was postulated, authors mostly proposed pharmacokinetically mediated effects via Cytochrome P450 2D6. Signals described in this review of potential adverse events should be examined in robust observational studies of specific beta-blocker-SSRI combinations. This will enable precise estimation of the magnitude of any associated risks and provide insight into the potential mechanism.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about fluoxetine